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Abstract
The toll-like receptor 5 (TLR5) agonist, CBLB502/Entolimod, is a peptide derived from bacterial flagellin and has been
shown to protect against radiation-induced tissue damage in animal models. Here we investigated the protective
mechanism of CBLB502 in the liver using models of ischemia-reperfusion injury and concanavalin A (ConA) induced
immuno-hepatitis. We report that pretreatment of mice with CBLB502 provoked a concomitant activation of NF-κB
and STAT3 signaling in the liver and reduced hepatic damage in both models. To understand the underlying
mechanism, we screened for cytokines in the serum of CBLB502 treated animals and detected high levels of IL-22.
There was no transcriptional upregulation of IL-22 in the liver, rather it was found in extrahepatic tissues, mainly the
colon, mesenteric lymph nodes (MLN), and spleen. RNA-seq analysis on isolated hepatocytes demonstrated that the
concomitant activation of NF-κB signaling by CBLB502 and STAT3 signaling by IL-22 produced a synergistic
cytoprotective transcriptional signature. In IL-22 knockout mice, the loss of IL-22 resulted in a decrease of hepatic
STAT3 activation, a reduction in the cytoprotective signature, and a loss of hepatoprotection following ischemia-
reperfusion-induced liver injury. Taken together, these findings suggest that CBLB502 protects the liver by increasing
hepatocyte resistance to acute liver injury through the cooperation of TLR5-NF-κB and IL-22-STAT3 signaling pathways.
Introduction
Hepatic diseases are a major health care burden
worldwide. In many cases, the necessary treatment option
for end-stage hepatic disease is liver transplantation,
however, less than 10% of the global transplantation needs
are currently met1. New methods of providing protection
against hepatic injury, thus ameliorating continued liver
dysfunction and failure, may provide support for this
shortcoming.
The innate immune system recognizes molecules
shared by pathogens through germ-line encoded toll-like
receptors (TLR). When activated, TLRs recruit toll/
interleukin-1 receptor (TIR) domain-containing adapter
proteins such as myeloid differentiation primary response
88 (MyD88) and TIR-domain-containing adapter-
inducing interferon-β (TRIF), which initiate signal trans-
duction pathways that culminate in the activation of
nuclear factor kappa B (NF-κB), interferon regulatory
factors (IRF), or mitogen-activated protein kinases
(MAPK)2. Regulation of TLR signaling is important as its
sustained activation can exacerbate an inflammatory
response resulting in cellular and tissue damage2, such as
the amplification of inflammation in rheumatoid arthri-
tis3, inflammatory bowel disease4, acute injury provoked
by ischemia-reperfusion5, and tissue fibrosis6. On the
other hand, judicious activation of TLRs can be beneficial
for tissue repair and protection by activating cytoprotec-
tive, anti-inflammatory signaling pathways6,7.
TLR5 is activated via the engagement of leucine-rich
repeat (LRR) ectodomains of TLR5 with its natural ligand,
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the three helices of the flagellin D1 domain8. TLR5 ago-
nists were shown to limit ischemia-reperfusion injury
(IRI) in the kidney9 and to decrease graft versus host
disease10. The beneficial effect of TLR5 activation has
been intensely investigated in the context of radiation-
induced toxicity, resulting in the development of the
optimized flagellin derivative, Entolimod, or CBLB502
(CBLB)11. Its proposed mechanism of protection is the
increased survival of intestinal and hematopoietic stem
cells by reducing inflammation and promoting anti-
apoptotic and redox modulating pathways12. Based on its
immunostimulatory effect and protective properties, the
use of CBLB has advanced towards clinical trials to pro-
mote antitumor responses, to reduce radiotherapy and/or
chemotherapy-induced side effects, and to be used as a
potentiating adjuvant during vaccinations (www.
clinicaltrial.gov. trial ref: NCT02715882, NCT03063736,
NCT01527136, NCT01728480).
Based on the studies demonstrating its protective
activity in normal tissue, we investigated the mechanism
of CBLB’s protection in the liver. We used two hepatic
injury models; IRI as a ROS and immune-induced hepatic
damage model13, and autoimmune-hepatitis induced by
concanavalin A (ConA) as a hepatocyte-apoptosis model.
Our results demonstrate that CBLB protects against
hepatic damage by protecting against parenchymal cell
death. The hepatoprotective effect is not solely achieved
by TLR5 activation on hepatocytes but requires con-
comitant signal transducer and activator of transcription 3




Animals were housed in specific pathogen‐free condi-
tions in accord with the Swiss veterinary office. Eight to
twelve weeks old C57BL/6J male and female mice (Harlan
Laboratories B.V., Horst, Netherlands), MyD88/TRIF
double knockout mice14, and IL-22 knockout mice15 were
acclimatized in a temperature‐controlled room with a
12 hours dark/light cycle and ad libitum access to water
and chow. CBLB was dissolved in saline and injected i.p.
(5μ l/g mouse) to reach a final concentration of 0.2 mg/kg
CBLB or an equivalent volume of saline (vehicle) in a
randomized (equal distribution of animals amongst cages)
and blinded (CBLB vs. Saline) 2 h prior to the IRI or ConA
challenge. IRI was induced by depriving the left lobe of
blood inflow for 1 h according to the previously described
procedure16. Serum was collected 6 h post-reperfusion
and mice were sacrificed at 24 h. Tissue from the left lobe
was fixed in 4% PFA for 48 h and snap-frozen. ConA
injury was provoked following a published protocol17 with
12mg/kg of ConA injected i.v. (Sigma-Aldrich, Darm-
stadt, Germany, #C7642). Mice were sacrificed after 8 h,
serum was collected, the left liver lobe was fixed in 4%
PFA for 24 h, and the right lobe was snap frozen. Animal
procedures were approved by the Veterinary Office of the
Canton Bern in line with institutional and standard pro-
tocols for the care and use of laboratory animals.
Measurement of serum alanine transaminase
Post‐injury serum samples were collected to assess the
extent of liver injury using alanine transaminase assay
(P800; Modular Analytics EVO, Roche, Mannheim, Ger-
many). The results were analyzed and displayed with
GraphPad Prism software, representing the mean and
standard deviation and analyzed using two-sided Stu-
dent’s t-test. (GraphPad Software Inc., La Jolla, CA, USA).
Histology
Hematoxylin and eosin staining and Gr1 immunohis-
tochemistry (eBioscience, San Diego, CA, USA, 4-5931-
85) were done following standard protocols previously
described16 and imaged with the Panoramic® 250 Flash III
slide scanner (3DHISTECH, Budapest, Hungary) using a
20x objective and the #DHISTECH acquisition software at
room temperature.
Myeloperoxidase assay
Proteins were extracted from total liver tissue and
myeloperoxidase (MPO) activity assay was carried out as
previously described16. The results were analyzed and
displayed with GraphPad Prism software, representing the
mean and standard deviation and analyzed using two-
sided Student’s t-test. (GraphPad Software Inc., La Jolla,
CA, USA).
Flow cytometry
Liver leukocytes were isolated by mechanical dissocia-
tion as described previously18. The following
fluorescently-labeled antibodies targeting mouse antigens
were used: CD45-BUV (BD Biosciences, Franklin Lakes,
NJ, USA, 30-F11), CD3-FITC (BioLegend, San Diego, CA,
USA, 17A2), NK1.1-APC-eFluor780 (eBioscience,
PK136), CD25-APC (ebioscience, PC61.5), and CD69-
PeCy7 (BD Biosciences, H1.2F3). Cells were acquired on a
SORP LSRII (BD Pharmingen Inc., San Diego, CA) and
flow cytometry data were analyzed using FlowJo software
(FlowJo, LLC) following the gating strategy given in
Supplementary Fig. 1. The results were analyzed and
displayed with GraphPad Prism software, representing the
mean and standard deviation and analyzed using two-
sided Student’s t-test. (GraphPad Software Inc., La Jolla,
CA, USA).
Serum cytokine measurements
Circulating cytokines and chemokines were assessed
using the magnetic bead array based ProcartaPlex mouse
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basic kit (#EXP010-20440-901) in combination with the
targets kit (Supplementary Table 1), following the man-
ufacturer’s instructions (eBioscience) and measured using
Luminex instrument (xMAP Technology). The results
were analyzed and displayed with GraphPad Prism soft-
ware, representing the mean and standard deviation.
(GraphPad Software Inc., La Jolla, CA, USA).
RNA isolation and quantification
RNA was isolated from snap-frozen tissue using TRIzol
(Sigma), quantified, and cDNA was generated using
Omniscript RT Kit 200 (Qiagen, Hilden, Germany) as
previously described19. qPCRs were performed using
TaqMan gene expression assays for Il22, Tbp, Socs3,
Hmox1, and Tnfaip3 (Thermo Fisher Scientific; Supple-
mentary Table 2). Il22 RNA was quantified following the
absolute quantification methods described by Pfaffl
et al.20. Tbp PCR product was cloned in a pGEM®-T Easy
Vector (Promega, Madison, WI, USA, #A3600), the
plasmid was amplified using the One Shot TOP10 Che-
mically Competent E. coli (Thermo Fisher Scientific) and
purified using the PureYield MaxiPrep (Promega). Il22
was quantified based on the Tbp standard, assuming a
perfect PCR efficacy. For the other targets, relative
changes in mRNA were calculated with the ΔΔCt method
using Tbp as a control gene. The results were analyzed
and displayed with GraphPad Prism software, represent-
ing the mean and standard deviation and analyzed using
two-sided Student’s t-test. (GraphPad Software Inc., La
Jolla, CA, USA).
Western blot
Western blots were done following previously used
protocols21,22 and the primary antibody for IκBα (Santa
Cruz Biotechnology, Dallas, TX, USA #sc371), and
STAT3 (#9139), phospho-STAT3-Tyr705 (#9145) or TBP
(#8415) all from Cell Signaling Technology (Danvers, MA,
USA), were used at a 1:1000 dilution, and the secondary
antibodies were anti-rabbit-HRP (Dako, Agilent technol-
ogy, Santa Clara, CA, USA) or anti-rabbit-680LT or anti-
mouse-800CW (LI-COR Bioscience, Lincoln, NE, USA).
Band densities were analyzed using ImageJ and displayed
with GraphPad Prism software, representing the mean
and standard deviation and analyzed using two-sided
Student’s t-test. (GraphPad Software Inc., La Jolla,
CA, USA).
Hepatocyte isolation and culture
C57BL/6 mouse hepatocytes were isolated in situ with
collagenase perfusion as previously described23, and cul-
tured on rat tail collagen coated plate in arginine free
Williams E media supplemented with 40mM ornithine,
100 iU/ml insulin, 2 mg/ml hydrocortisone, penicillin, and
streptomycin. Twenty-four hours after plating, the
hepatocytes were treated with CBLB (4 ng/ml Cleveland
BioLabs, Buffalo, NY, USA) and/or IL-22 (1 ng/ml;
PeproTech, Rocky Hill, NJ, USA, #210-22) in
combination.
Transcriptomic and pathway analysis
RNA was extracted from snap-frozen tissue with
RNeasy Micro Kit (Qiagen; 74004), quantified by Qubit
BR assay (Thermo Fisher Scientific) and quality assessed
by Fragment Analyzer (Advanced Analytical, Parkersburg,
WV, USA) using Standard Sensitivity RNA Analysis Kit
(Advanced Analytical, #DNF-471). The library was pre-
pared without size exclusion with the TruSeq Stranded
mRNA kit (Illumina, San Diego, CA, USA, #20020594).
Qubit dsDNA HS (Thermo Fisher Scientific; #Q32851)
and Fragment Analyzer NGS Kit (Advanced Analytical;
#DNF-474) were used for library quality control. Finally,
the samples were sequenced on a NovaSeq6000 (Illu-
mina), paired-end 1 x 50 bp on one lane. Fastq files were
aligned to the mouse reference genome mm10 with
HISAT224. The resulting SAM files were transformed into
sorted BAM files with SAMTOOLS25. Further analysis
was done using the RStudio software
The counts were counted from the bam files with fea-
tureCounts R function of the R package Rsubread26.
Differentially expressed genes (DEG) were assessed using
DESeq227. In every condition (control, CBLB, IL-22,
CBLB+ IL-22), a paired comparison within each isolation
replicate was performed. In order to visualize the data in
two dimensions, we transformed the data into reads per
million (RPM) and performed a principal component
analysis with the R function prcomp. The new resulting
coordinates (PC1 and PC2) were translated to move the
Control to the position 0, 0, that is fi(x,y)= (xi− cx,i, yn−
cy,i), with (i= 1, 2, 3) denoting the hepatocytes isolation
experiment. Gene Log10(p value) and Log2(fold change)
(log2FC) changes for each condition were visualized using
volcano plots with the gene with an adjusted p value <
0.05 and −1 < Log2FC > 1 were colored in green. A
heatmap figure was produced using normalized gene
expression with the maximum expression set to 1 and the
minimum to 0, using the function heatmap.2 from the R
package28, with complete linkage using correlation
distance.
The stackplots showing the pathways were performed
with a custom R script. First, we selected the ten most
significant families of pathways identified by Metascape.
Second, we obtained all the genes involved with the R
function gconvert of the R package gprofiler2. Third, we
computed the intersection between the gene lists and the
statistically significant differentially expressed and colored
according to log2FC. The significance of each pathway
was assessed by Metascape. For the p53 signaling pathway
(mmu04115), the genes were manually included from the
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Metascape output. The bar plots showing the 20 most
significant families of pathways were done with
Metascape.
Results
TLR5 agonist CBLB is hepatoprotective in vivo
The effect of CBLB against oxidative stress generated by
ischemia-reperfusion and by immune-driven hepatic
damage caused by ConA was tested in mice pretreated
with CBLB for 2 h (Fig. 1A, F). Following 1 h of partial
liver ischemia and 6 h reperfusion, serum ALAT levels
elevated to 2883I.U. in control animals, whereas ALAT
levels only increased to 688I.U. in animals pretreated with
CBLB (Fig. 1B). Twenty-four hours after reperfusion, the
livers of CBLB treated mice displayed smaller necrotic
areas (Fig. 1C), which was accompanied by a reduction of
MPO activity (Fig. 1D) resulting from the decreased
neutrophil infiltration (Fig. 1E). In the ConA model, CBLB
pretreated animals had a tenfold decrease of ALAT serum
levels (from 11186I.U. to 1068I.U.) following ConA
challenge compared to control (Fig. 1G), and a decrease in
necrotic areas compared to controls (Fig. 1H). T cells and
NKT cells are the primary effector cells in mediating
ConA injury17,29. In control mice treated with ConA,
there was an increase in the percentage of T cells in the
infiltrating CD45+ cells (Fig. 1I), and a reduced percen-
tage of NKT cells (Fig. 1J). In both T and NKT cells, there
was an increase in their activation markers CD25 and
CD69, with more double-positive cells present (Fig. 1K,
L). CBLB did not alter the percentage of infiltrating
immune cells nor did it modify their activation marker
expression upon ConA challenge (Fig. 1I–L). Taken
together, our in vivo data suggests that pretreatment with
CBLB prevents hepatic damage in both IRI and ConA
liver injury, as determined by the early reduction in serum
ALAT levels. As there was no difference in the NKT and
T cell infiltration and activation in the ConA model, this
suggested that CBLB did not alter the immune cell infil-
tration and activation, but rather may enhance the resis-
tance of hepatocytes to harmful stimuli.
CBLB induces hepatic STAT3 activation and remote IL-22
production
Previous reports have shown that CBLB activates both
NF-κB and STAT3 signaling pathways in vivo12. As CBLB
is known to directly activate the NF-κB pathway via
TLR5 signaling30, we explored the origin of the CBLB-
induced STAT3 activation in the liver. Two hours post-
injection, CBLB induced the phosphorylation of tyrosine
705 of STAT3 in liver tissue (Fig. 2A) As STAT3 signaling
is mainly mediated by Janus kinases upon cytokine sti-
mulation31, we evaluated the serum of mice for 22 cyto-
kines and chemokines 2 and 6 h following CBLB
exposure. TLR5 activation did not increase the serum
level of 13 of the tested cytokines, IL-1β, IL-4, IL-10, IL-
12p70, IL-13, IL-15/IL-15R, IL-17A, IL-17F, IL-23, IL-33,
TNFα, INFα, and INFγ (Supplementary Fig. 2), whereas
nine other cytokines were elevated in the serum with a
peak 2 h post-injection. There was a minor increase of the
chemokine CCL5 and a greater than tenfold increase of
CCL2, CXCL1, and CXCL2 to ~100 pg/ml. The pro-
inflammatory cytokine IL-1α was increased to 50 pg/ml
and IL-6 and IL-18 were increased to around 200 pg/ml.
For cytokines involved in wound healing, IL-5 showed a
minor response, whereas serum levels of IL-22 reached an
average level of 1670 pg/ml (Fig. 2B). IL-22 is an anti-
fibrotic cytokine, that prevents liver injury, promotes liver
regeneration32,33, and was shown to protect against both
hepatic IRI and ConA-induced liver damage34,35. Conse-
quently, we considered IL-22 as a possible contributor to
the hepatoprotective effect of TLR5 activation.
To assess if the increase of IL-22 in the serum of CBLB
treated mice was due to TLR5 signaling, CBLB was
administered to MyD88/TRIF double KO mice. There
was no increase in serum IL-22 levels, suggesting that
CBLB increased levels of IL-22 in a TLR5-MyD88-TRIF-
dependent manner (Fig. 2C). We next questioned if the
increase of IL-22 serum levels was a direct and localized
response from the liver. We observed no transcriptional
increase of IL-22 in the liver tissue of mice 2 and 6 h
following CBLB injection (Fig. 2D). To then determine the
source of IL-22 detected in serum, we screened 17 organs
for IL-22 mRNA expression following CBLB exposure.
There were no detectable levels of IL-22 mRNA in all
organs prior to CBLB injection, nor in the pancreas, bone
marrow, skin, kidney, brain, muscle, heart, and blood 2 h
post-injection (Supplementary Fig. 3). In the colon and
MLN, there was a strong increase in IL-22 mRNA, and to
a smaller extent also in the intestine, spleen, thymus, lung,
salivary gland, and stomach. After 6 h, IL-22 mRNA levels
were lower in all organs, with the exception of the MLN
that showed a 2.5 times higher level of IL-22 transcript
compared to values at 2 h (Fig. 2D and Supplementary Fig.
3). Taken together, our data demonstrate that in addition
to NF-κB activation, STAT3 is activated in the liver of
mice exposed to CBLB. STAT3 activation can be a result
of TLR5-induced cytokine expression, particularly IL-22.
We furthermore conclude that IL-22 is not produced in
the liver, but rather remotely in the colon and MLN.
Pathway analysis of hepatocytes stimulated with CBLB and
IL-22
We next questioned if CBLB and/or IL-22 directly alter
the transcriptional profile of hepatocytes thus explaining
its hepatoprotective effect. We first validated that hepa-
tocytes have a direct response to TLR5 activation and IL-
22 by treating primary mouse hepatocytes with CBLB and
IL-22 and measuring downstream receptor signaling.
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Fig. 1 CBLB decreases hepatic damage. A Experimental plan of ischemia-reperfusion study, vehicle n= 4, CBLB n= 5 mice. B Serum ALAT 6 h after
reperfusion. C Representative H&E image of liver tissue 24 h post-reperfusion. D Tissue myeloperoxidase activity 24 h post-reperfusion. E
Representative images of liver Gr1 immunohistochemistry 24 h post-ischemia-reperfusion. F Experimental plan of ConA model, vehicule n= 8, CBLB
n= 8. G Serum ALAT 8 h after ConA challenge. H Representative H&E image of liver tissue 8 h following ConA injection. FACS analysis of I T cell and
J NKT cells frequency represented as a percentage of CD45+ cells extracted from the liver 8 h ConA injection. FACS analysis of the activation
frequency of K T cell and L NKT cell markers CD25 and CD69. Frequencies are represented as a percentage of CD45+ cells extracted from liver 8 h
post-ConA injection.
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CBLB led to the activation of the NF-κB, indicated by the
degradation of its inhibitory protein IκBα but did not lead
to STAT3 phosphorylation (Fig. 3A and Supplementary
Fig. 4). IL-22 induced the phosphorylation of STAT3 on
tyrosine 705, signifying activation of STAT3 transcrip-
tional activity but did not result in the activation of NF-κB
(Fig. 3A and Supplementary Fig. 4). The downstream
transcriptional response was measured by bulk RNA-seq
in hepatocytes isolated from three mice that were treated
with either CBLB or IL-22 alone or in combination
(CBLB+ IL-22) for 2 h. The first principal component
(PC1) indicated a strong combinatorial effect of CBLB+
IL-22, which clustered to the right compared to the
control, IL-22 and CBLB treated cells, clustered to the left.
In the second principal component (PC2), differences
between control and CBLB groups could be observed (Fig.
3B). We next assessed the distribution of statistically
significant DEG in the three treatment conditions
compared to their untreated controls. CBLB treated
hepatocytes displayed 1771 downregulated and 2045
upregulated DEG. The effect of IL-22 on hepatocytes was
minor; only 52 downregulated and 100 upregulated DEG
were observed. The combination of CBLB+ IL-22 resul-
ted in 1184 downregulated and 1587 upregulated DEG.
Although the exposure to IL-22 only induced a small
effect, adding IL-22 to CBLB altered the response to
CBLB alone. Indeed, the addition of IL-22 to CBLB
decreased the overall number of DEG and considerably
increased their fold change intensity (Fig. 3C).
Next, we questioned if the changes in the DEG between
the groups were the same. Gene overlap analysis was
performed using the multiple gene list function on
Metascape and was then displayed in a Circos plot. IL-22
had no unique DEG; all were shared with the CBLB+ IL-
22 group. While CBLB and CBLB+ IL-22 had shared
DEG, both also had a majority of non-overlapping, unique
Fig. 2 CBLB induces a remote IL-22 release that triggers hepatic STAT3 signaling. A Western blot analysis of liver STAT3 and STAT3
phosphorylated at tyrosine 705 at control, 2 h, and 6 h following CBLB injection, and its STAT3 phosphorylated at tyrosine 705/STAT3 ratio, n= 3 mice
per group. B Analysis of mouse serum 2 h post-CBLB injection, n= 7 mice. C IL-22 serum levels in WT and MyD88/Trif double knockout mice 2 h post-
CBLB injection, n= 4 mice per group. D RNA expression in various tissue 2 and 6 h post-CBLB injection, n= 3 mice per group.
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Fig. 3 CBLB and Il-22 induce hepatocyte NF-κB and STAT3 signaling, respectively. A Western blot analysis of hepatocytes for IκBα normalized
by TBP and STAT3 phosphorylated at tyrosine 705 normalized by STAT3 at control, 20, 40, and 60min after CBLB or IL-22 exposure, n= 2 replicates
per time point. B The PCA of the transcriptomic signature of hepatocytes treated for 2 h with either CBLB in red, IL-22 in green, CBLB+ IL-22 in blue,
or control in black. The isolation replicates are indicated with the same shape, n= 3 replicates. C Volcano plot displaying the differentially expressed
genes (DEG) of each condition compared to control, showing the DEG with a −1 < Log2FC > 1 in green. D Circos plot showing on the outer ring the
treatment groups and on the inner ring the DEG. DEG that are shared by the different groups are indicated in dark orange, DEG unique to each
group are in light orange. Each gene shared between the different groups is indicated by purple lines. E Bar graph presenting the ten most regulated
pathways of each condition, with the number of DEG upregulated in red or downregulated in blue for each condition. F Heat map of the
inflammatory response pathway showing the DEG with a −1 < Log2FC > 1, with genes known to be hepatoprotective in IRI or ConA models in bold.
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DEG (Fig. 3D) which is further displayed as a heatmap in
Supplementary Fig. 5.
To evaluate the functional consequences elicited by
each treatment, we performed a pathway enrichment
analysis using Metascape which generated a list of 40
pathways associated with up- and down-regulated DEG
for each condition (Supplementary Fig. 6). Based on p
values ranging from −log(p) 8.4 to 19.6, the ten most
regulated pathways in hepatocytes treated with CBLB
alone were comprised of downregulated genes involved in
metabolic processes, and upregulated genes are involved
in apoptotic signaling and cell cycle regulation. Interest-
ingly, aside from the upregulation of genes involved in the
TNF signaling pathway, we did not identify the regulation
of genes involved in inflammatory, cytokine, or immune
response pathways (Fig. 3E and Supplementary Fig. 6).
Pathway enrichment analysis of DEG in IL-22 treated
hepatocytes resulted in pathways with −log(p) values
below 10. The ten most regulated pathways showed an
upregulation of genes associated with inflammation,
cytokine and immune response, and a downregulation of
genes associated with metabolism (Fig. 3E and Supple-
mentary Fig. 6).
The most significantly regulated pathways, with p values
ranging from −log(p) 15.5 to 36.2 were found in the
CBLB+ IL-22 group and were associated with the upre-
gulation of genes involved in NF-κB and apoptotic sig-
naling, as well as inflammatory, cytokine and immune
response pathways. The −log(p) values of the pathways
associated with downregulated genes in the CBLB+ IL-22
group were all below 9.5. (Fig. 3E and Supplementary Fig.
6).
We further investigated the pathway with the highest p
value across all groups, which was the inflammatory
response, and computed a heat map for all the DEG with a
fold change below 0.5 or above 2. Strikingly, the combi-
nation of CBLB+ IL-22 resulted in the upregulation of a
large gene set (Fig. 3F). Among those genes strongly
upregulated by CBLB+ IL-22, we found inhibitors of
inflammatory processes such as Nfkbia, Nfkbid, Nfkbiz,
Sbno2, Socs1, Socs3, Socs5, and Tnfaip3, and genes reg-
ulating redox homeostasis like Hif1a, Hmox1, Nos2, and
Sod2, and antiapoptotic genes Tnfaip3 (Supplementary
Figs. 7 and 8). The transcriptomic analysis suggests that
the combination of CBLB+ IL-22 incites a cytoprotective
signature that is not accomplished by either of the two
treatments alone.
IL-22 is required for CBLB-induced hepatoprotection
From the data presented above, IL-22 appeared to have
a key role in CBLB-mediated hepatoprotection. For fur-
ther validation, we assessed the hepatoprotective effect of
CBLB in IL-22 knockout (IL-22−/−) mice. Firstly, we
examined STAT3 activation in the livers of mice following
CBLB injection and observed a reduction of STAT3
phosphorylation in IL-22−/− mice (Fig. 4A). Furthermore,
the livers of IL-22−/− mice had an attenuated transcrip-
tional increase of the cytoprotective genes, Tnfaip3,
Hmox1, and Socs3 in response to CBLB compared to wild
type controls (Fig. 4B). Finally, compared to wild-type
animals in which CBLB significantly decreased ALAT
levels following ischemia-reperfusion, this hepatoprotec-
tive effect of CBLB was diminished in IL-22−/− animals
(Fig. 4C). Altogether our data suggest that IL-22 is con-
tributing to CBLB-mediated hepatoprotection.
Discussion
We show that preconditioning mice with the TLR5
agonist CBLB protected them from ischemia-reperfusion
and ConA-induced liver injuries. Previous reports support
the protective activity of CBLB in models of renal injury
and immune-mediated hepatitis, but they focused on the
immunomodulatory effect of CBLB, for example, its
ability to dampen the immune response9,36. In our mod-
els, we did not observe an altered immune reactivity in
mice pretreated for 2 h with CBLB, namely in NKT and T-
cell activation markers, thus suggesting a potential
increased resistance within the hepatocytes themselves to
injurious stimuli. In agreement with our data, both NF-κB
and STAT3 signaling and have been demonstrated to be
activated in the liver of mice treated with CBLB12. As
there is no evidence to directly link TLR5 with STAT3
activation, we investigated an indirect effect which could
trigger STAT3 activation by focusing on a CBLB-induced
cytokine and chemokine response. Our results show an
increase in serum levels of chemoattractant (CCL2, CCL5,
CXCL1, and CXCL2), pro-inflammatory (IL-1α, IL-6, and
IL-18), and wound healing associated-cytokines (IL-5, IL-
22), which is in agreement with the current knowledge of
a cytokine response expected following exposure to TLR5
agonists37–41. Notably, levels of IL-22 were the highest
amongst the cytokines measured. IL-22 signals through
IL-22Rα and IL-10Rβ, triggering STAT3 signaling and has
been reported to promote liver regeneration and to
decrease liver fibrosis and injury32–35. We demonstrated
that IL-22 secreted after CBLB treatment was not origi-
nating from the liver, but from extrahepatic sources,
namely organs upstream of the portal vein, such as colon,
MLN, spleen, and intestine. This finding is strengthened
by the identification of the IL-22 producing cells as CD3−,
CD127+ immune cells from the spleen and mucosa in
response to TLR5 activation38. Based on these observa-
tions, we suppose that IL-22 produced by those visceral
organs, circulates via the portal blood flow into the liver
and triggers the activation of STAT3 signaling.
To better understand how CBLB could increase the
resistance of hepatocytes to damage, we evaluated the
effect of CBLB and IL-22 alone or in combination in
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isolated mouse hepatocytes. As expected, CBLB led to the
activation of the NF-κB pathway and resulted in a robust
transcriptional response. Interestingly, the majority of the
pathways affected were associated with the down-
regulation of genes associated with metabolism. Recent
work reporting a hepatocyte-specific deletion of the TLR
downstream adapter protein MyD88, also demonstrated
an alteration of hepatic bile acid, glucose, and lipid
metabolic functions, supporting our observations42.
Although we expected to observe a strong inflammatory
response, we only observed activation of the TNF sig-
naling pathway. Through further inspection of the
regulated pathways of CBLB stimulated hepatocytes, we
could not show CBLB-induced signaling as responsible
for the hepatoprotection we observed in vivo. IL-22Rα is
constitutively expressed by epithelial cells, including
hepatocytes43. Treating primary hepatocytes with IL-22
resulted in STAT3 pathway activation; however, the
transcriptomic changes were minor. The main pathway
affected by IL-22 was the inflammatory response pathway,
but only 18 genes were upregulated. This result was
unexpected based on the proven activity of
STAT3 signaling in vivo in promoting cell survival, pro-
liferation, IRI, and ConA protection34,35.
Fig. 4 IL-22 is required to mediate CBLB hepatoprotection. A Western blot analysis of proteins extracted from the livers of WT and IL-22−/− mice
for total STAT3 and STAT3 phosphorylated at tyrosine 705, 2 h following CBLB injection and the corresponding STAT3 phosphorylated at tyrosine
705/STAT3 ratio, n= 3 mice per group. B qPCR of three of the cytoprotective genes (Tnfaip3, Hmox1, and Socs3) in WT and IL-22−/− mice 2 h
following CBLB injection, n= 3 mice per group. C Serum ALAT levels 6 h after reperfusion.
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Often transcription factors require transcriptional
cooperation in order to initiate gene transcription and
interestingly, NF-κB and STAT3 have been largely studied
for their transcriptional collaboration44. Contrary to the
effect they elicit alone, the combination of CBLB+ IL-22
induced a strong upregulation of genes involved in the
inflammatory response pathway. The transcriptional
effect of CBLB+ IL-22 contains inhibitors of inflamma-
tion, apoptosis, and modulators of redox processes that
are regulated following CBLB or IL-22 alone. For exam-
ple, there was an upregulation of NF-κB pathway inhibi-
tors (Nfkbia, Nfkbid, Nfkbiz, and Sbno2) that could be
expected to reduce IRI damage, as NF-κB activation was
shown to worsen the hepatic damage in IRI and ConA
models45,46. In addition, the Socs protein family inhibits
pathways such as insulin, IFNγ TLR, and p38/JNK sig-
naling also known to exacerbate IRI and ConA injury17,45–51.
Furthermore, genes involved in redox modulation, such as
Hif1a, Hmox1, Nos2, and Sod2, were shown to promote
resistance in IRI models52. Finally, we identified an
induction of antiapoptotic genes such as Tnfaip3 known
to promote survival in both hepatic IRI and ConA-
induced hepatitis models53,54.
As the synergic treatment of CBLB and IL-22 activates a
hepatoprotective transcriptional response in hepatocytes
in vitro, we evaluated the difference of response of CBLB
in IL-22−/− mice. In response to CBLB, IL-22−/− mice
showed a decrease of 60% in STAT3 signaling compared
to WT mice. Other cytokines induced by CBLB, such as
IL-6 and IL-18, are known to activate STAT signaling and
might explain the remaining 40% of STAT3 phosphor-
ylation55,56. We then confirmed in vivo the liver activation
of three of the cytoprotective genes induced in hepato-
cytes with combined CBLB and IL-22 treatment. Tnfaip3,
Hmox1, and Socs3 were strongly upregulated in the livers
of WT mice, but this upregulation was absent or dimin-
ished in IL-22−/− mice. Moreover, CBLB was not able to
provide the same amount of protection in the IL-22−/−
mice against ischemia-reperfusion injury. This result is
concordant with the known literature on the protective
activity of IL-2234, TNFAIP353, HMOX152, and SOCS346–49
in ischemia-reperfusion injury.
Taken together, our data demonstrates that pre-
conditioning the liver with CBLB is protective against
acute hepatic injury. CBLB induces a hepatoprotective
transcriptional response in hepatocytes through a direct
activation of TLR5—NF-κB signaling in hepatocytes, as
well as the induction of STAT3 signaling indirectly via the
production of IL-22 from the colon and MLN (Fig. 5).
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